Sign in
CG

Cronos Group Inc. (CRON)·Q1 2025 Earnings Summary

Executive Summary

  • Q1 2025 delivered accelerating topline and margin improvement: revenue rose 28% YoY to $32.3M and gross margin expanded to 43% (adjusted gross margin 44%) on mix shift (Israel/international flower) and lower direct costs/efficiencies .
  • Results beat S&P Global consensus: revenue $32.3M vs $31.6M*, GAAP EBITDA -$1.3M vs -$3.0M*, and diluted EPS $0.02 vs -$0.00*; non‑GAAP Adjusted EBITDA was positive $2.3M, up $13.0M YoY .
  • Management authorized a $50M buyback (up to ~19.27M shares; 5% of OS), highlighting balance sheet strength (cash + ST investments $837.8M) and capital return optionality .
  • Narrative/catalysts: near‑term supply constraints in Canada (strong Spinach demand) should ease as the GrowCo expansion completes in Q2 with initial sales in H2 2025, supporting growth in Canada, Israel, Germany and the UK; monitoring Israel’s proposed anti‑dumping tariffs as a key regulatory swing factor .

What Went Well and What Went Wrong

  • What Went Well

    • Material revenue and margin inflection: revenue +28% YoY to $32.3M; gross margin +25pp YoY to 43%; Adjusted EBITDA turned to +$2.3M, +$13.0M YoY, driven by higher flower sales (Israel/intl), Canadian extracts, lower costs and efficiencies .
    • Brand leadership: Spinach ended Q1 as #2 brand in Canada (4.6% share) and #4 in vapes (5.7%); SOURZ held ~20% gummy share; PEACE NATURALS posted record revenue and volume in Israel with #1 share .
    • Balance sheet and capital return: $797.8M cash plus $40.0M ST investments; $50M share repurchase authorized through May 2026 (max ~19.27M shares) .

  • What Went Wrong

    • Supply constraints curtailed Spinach growth in flower; management is allocating inventory and expects GrowCo capacity to alleviate shortages in H2 2025 .
    • Regulatory overhang in Israel: proposed anti‑dumping duties up to 165% on Canadian medical cannabis remain in process despite Finance Minister’s veto; company is actively opposing tariffs and warns of potential patient harm if implemented .
    • Margin normalization expected: CFO flagged timing benefits in Q1 GM; underlying margin viewed as a blend of Q4 and Q1; OpEx to run higher than Q1 over the balance of 2025 (flat YoY overall), and CapEx to stay temporarily elevated to complete GrowCo .

Financial Results

Quarterly performance (oldest → newest):

MetricQ3 2024Q4 2024Q1 2025
Revenue ($USD)$34.264M $30.301M $32.262M
Diluted EPS ($)$0.02 $0.11 $0.02
Gross Margin (%)11% 36% 43%
Adjusted Gross Margin (%)31% 30% 44%
Adjusted EBITDA ($USD)$(6.0)M $(7.2)M $2.289M

Q1 2025 actuals vs S&P Global consensus:

MetricActualS&P ConsensusSurprise
Revenue ($USD)$32.262M $31.597M*+$0.665M / +2.1%*
Diluted EPS ($)$0.02 -$0.00*+$0.02*
EBITDA ($USD)$(1.304)M*$(2.952)M*+$1.648M*

Values marked with * retrieved from S&P Global.

Segment/product and geographic mix (Q1 2025 vs Q1 2024):

Net RevenueQ1 2024Q1 2025YoY Change
Cannabis flower$17.525M$23.344M+33%
Cannabis extracts$7.727M$8.608M+11%
Other$0.036M$0.310M+761%
Total$25.288M$32.262M+28%
GeographyQ1 2024Q1 2025YoY Change
Canada$18.871M$20.130M+7%
Israel$6.417M$9.229M+44%
Other countries$0.000M$2.903MN/A
Total$25.288M$32.262M+28%

KPIs and balance sheet:

KPIQ4 2024Q1 2025
Gross profit ($USD)$10.807M $13.734M
Net income ($USD)$43.941M $7.723M
Cash & cash equivalents ($USD)$858.805M $797.819M
Short-term investments ($USD)$0.000M $40.000M
Cash + ST investments ($USD)$858.805M $837.819M
Capital expenditures ($USD)$3.708M $15.356M
Cash from operations ($USD)—$(2.096)M

Non‑GAAP context: Adjusted Gross Profit $14.251M and Adjusted EBITDA $2.289M in Q1 2025, with inventory step‑up of $0.517M recognized in cost of sales due to GrowCo purchase accounting .

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
GrowCo expansion timing2025Finish construction in Q2 2025; first harvest/sales H2 2025 On track: completion Q2; initial sales H2 2025 Maintained
Gross margin outlook2025—Underlying margin viewed as blended Q4’24 and Q1’25; Q1 included timing benefits New qualitative color
Operating expenses20252024 standalone OpEx -$5–$10M achieved; 2025 OpEx flat (incl. GrowCo) 2025 quarterly OpEx higher than Q1 level; relatively flat YoY Clarified
CapExH1–Q3 2025Elevated due to GrowCo To remain elevated next couple of quarters; normalize lower post-completion Maintained/updated cadence
Share repurchasesMay 14, 2025–May 13, 2026—Up to $50M; max ~19,270,951 shares (5% OS) New

Earnings Call Themes & Trends

TopicPrevious Mentions (Q3 2024, Q4 2024)Current Period (Q1 2025)Trend
Supply constraints / product shortagesBuilding demand; Spinach #1 flower; warned growth to pause until H2’25 capacity Spinach constrained in flower; deliberate allocation; capacity relief in H2’25 Near-term constraint; easing with GrowCo
GrowCo expansionConsolidation; expansion funded; finish Q2’25; sales H2’25 “On track” for Q2 completion; H2 sales begin On plan
International (Israel)Record volume; #1 share; competitive market and conflict Record revenue/volume; ~30% of consolidated revenue; tariff risk highlighted Strong performance; regulatory overhang
International (Germany/UK)Early traction; expand with proprietary genetics Expect further growth as capacity ramps; momentum in UK Positive
Product innovationRare‑cannabinoid vapes, SOURZ launches, Lord Jones leadership New Spinach 1.2g vapes and 10mg SOURZ Fully Blasted flavors; Lord Jones #3 chocolates Sustained leadership
MarginsAdjusted GM 30% in Q4’24; improvement YoY GM 43% (Adj 44%); timing benefits noted; blend Q4/Q1 as underlying Improving; normalize
OpEx discipline2024 standalone OpEx -$8.7M; 2025 flat Q1 benefited from bonus reversal/timing; expect higher run‑rate than Q1 but flat YoY Controlled

Management Commentary

  • “2025 is shaping up to be a transformative year… GrowCo expansion… on track for completion in the second quarter with initial sales in the second half of the year, will unlock significant capacity to meet this demand and fuel our next phase of growth.” — Mike Gorenstein, CEO .
  • “Adjusted gross margin… 44%… a significant improvement from 18% in Q1 2024… driven by regional mix, lower direct costs and production efficiencies… Given timing benefits, we would view the blended adjusted gross margin over Q4 2024 and Q1 2025 as more indicative.” — Anna Shlimak, CFO .
  • “Israel… was a record quarter across the P&L… As the top medical provider in Israel… we will continue to advocate… opposing these tariffs.” — Mike Gorenstein .

Q&A Highlights

  • Supply shortages: CFO noted a shortage of “good product in market,” underscoring rationale for GrowCo expansion to scale leading genetics across Canada and Israel .
  • Margin cadence: Underlying gross margin expected to align with a blend of Q4’24 and Q1’25; GrowCo expansion should be neutral to accretive over time as fixed costs are leveraged; ramp will take time .
  • Transcript clarification: One transcript version cited ~$50M working capital outflow and ~$50M CapEx; the filed Q1 2025 8‑K indicates CapEx ~$15.3M and operating cash flow of $(2.1)M with working capital headwinds (e.g., accrued liabilities and receivables), which should be used as authoritative .

Estimates Context

  • S&P Global consensus for Q1 2025: revenue $31.6M*, GAAP EBITDA $(3.0)M*, EPS -$0.00* (4 ests for EPS, 2 ests for revenue). Actuals: revenue $32.3M (beat), GAAP EBITDA $(1.3)M (beat), diluted EPS $0.02 (beat). Non‑GAAP Adjusted EBITDA was $2.3M, not directly comparable to consensus GAAP EBITDA .
    Values marked with * retrieved from S&P Global.

Key Takeaways for Investors

  • Revenue and margin momentum is real: mix shift to international flower and lower costs drove GM to 43% and Adjusted EBITDA positive; expect margins to normalize toward a Q4/Q1 blend near term .
  • Capacity unlock is the key 2H catalyst: GrowCo expansion (Q2 completion; H2 sales) should relieve Spinach flower constraints, enabling share recapture in Canada and further growth in Israel/Germany/UK .
  • Regulatory swing factor in Israel: watch the anti‑dumping duty process; adverse duty would pressure price/mix but management is actively contesting and cited strong patient leadership .
  • Balance sheet optionality + buyback: $838M of liquidity (cash + ST investments) and $50M repurchase authorization provide downside support and capital flexibility .
  • Estimates likely to drift up on revenue/margin trajectory and demonstrated execution, but model near‑term GM/OpEx normalization and staged GrowCo ramp to avoid over‑extrapolating Q1 timing benefits .
  • Trading setup: H2 execution on capacity ramp and clarity on Israel tariffs are likely stock movers; continued category leadership (SOURZ gummies, vapes; PEACE NATURALS in Israel) supports relative outperformance narrative .

Additional detail

  • Business updates: market share leadership and product launches (Spinach 1.2g rare‑cannabinoid vapes; SOURZ Fully Blasted 10mg gummies; Lord Jones category leadership) reinforce brand strength in key categories .
  • Non‑GAAP adjustments: Inventory step‑up from GrowCo ($0.517M in Q1) suppressed GAAP gross profit/margins; Adjusted metrics remove purchase accounting to depict underlying performance .